A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.
Somm E, Bonnet N, Martinez A, Marks PM, Cadd VA, Elliott M, Toulotte A, Ferrari SL, Rizzoli R, Hüppi PS, Harper E, Melmed S, Jones R, Aubert ML.
Somm E, et al.
J Clin Invest. 2012 Sep;122(9):3295-306. doi: 10.1172/JCI63232. Epub 2012 Aug 1.
J Clin Invest. 2012.
PMID: 22850878
Free PMC article.